Forty-eight-hour polysomnographic evaluation of narcolepsy.

Eleven narcoleptic and 11 control subjects completed five multiple sleep latency test (MSLT) procedures with instructions to "fall asleep" while supine and five maintenance of wakefulness test (MWT) procedures with instructions to "remain awake" while comfortably sitting. Narcoleptic subjects had a shorter sleep latency and a higher frequency of sleep onset REM periods (SOREMPs) on both daytime tests than controls. Each group had a longer sleep latency on the MWT than MSLT.

Obstructive sleep apnea and body weight.

A patient with obstructive sleep apnea was monitored five times during three years while his weight fluctuated within a range of 26 kg. The number of apneas per hour of sleep varied from 59.6 at 111 kg of weight to 3.

Long acting delivery systems for narcotic antagonists II: release rates of naltrexone from poly(lactic acid) composites.

Parallel in vitro and in vivo release rates of tritiated naltrexone from poly(lactic acid) composites were studied. The in vitro release of naltrexone was 67% of the dose over a 35-day test period, while the in vivo release was only 24% within 70 days. Apparently, an exchange of the tritium for the hydrogen of the body water takes place, indicating that urinary excretion radioactivity is not a reliable measure for estimating the naltrexone released.

Timed-release depot for anticancer agents.

The timed-release of anticancer agents from composities with poly (lactic acid) was studied in rats. In the case of cyclophosphamide-poly (lactic acid) composites, 67% of the administered dose was released within 34 days. With cis-dichlorodiammineplatinum (II), the amount of drug released was only 9.